8-K ·Filed May 4, 2026

INDV

Indivior Pharmaceuticals, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed5mo ago SEC0001625297-26-000021
8-K context-dependent: Items 7.01, 8.01
Actionable Insight • Neutral

The ASR is a routine capital return move with no earnings or guidance implications. Mildly supportive for stock price due to reduced share count, but not a catalyst. Monitor future earnings releases for fundamental trends.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
INDV ▲ +2.87% at T+60d
NEUTRAL call ✓ call won +2.87% · α vs SPY +1.02% · entry $38.98 → $40.10
Entry anchored
May 1, 03:59 PM ET
via exchange tick
T+1d
+1.56%
call +1.56% · α +0.77%
$39.59
settled 5mo ago
T+5d
-0.36%
call -0.36% · α -3.30%
$38.84
settled 5mo ago
T+20d
-10.52%
call -10.52% · α -16.16%
$34.88
settled 4mo ago
T+60d
+2.87%
call +2.87% · α +1.02%
$40.10
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

Indivior entered into a $175 million accelerated share repurchase agreement with Barclays as part of its existing $400 million buyback program, receiving an initial 3.7 million shares. The transaction is expected to settle by June 22, 2026, and does not impact previously issued financial guidance.

Key Facts

  • $175 million accelerated share repurchase agreement with Barclays Bank PLC
  • Initial delivery of 3,717,473 shares
  • Part of previously authorized $400 million share repurchase program
  • Final settlement expected by June 22, 2026
  • $100 million remains available for additional repurchases

Financial Impact

$175 million cash outlay for share repurchase; EPS accretive depending on final share count reduction

cashshares outstandingeps

Risk Factors

  • Execution risk if stock price declines during ASR term, potentially reducing final share count
  • Opportunity cost of deploying $175M into buybacks instead of R&D or acquisitions

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (13 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001625297-26-000021
Exhibit: ex991asrpressreleasemay420.htm0001625297-26-000021
Document: 0001625297-26-000021-index-headers.html0001625297-26-000021
Document: 0001625297-26-000021-index.html0001625297-26-000021
Document: 0001625297-26-000021.txt0001625297-26-000021
18 reports for INDV
Performance horizon
100% Hit rate 7 of 7 directional calls best @ T+60▲ +21.73%Apr 24, 2026
Filters
Rows
Reports for INDV — sortable, filterable
TypeNow
Sep 14, 2026
18d ago
EFFECT
NEUTRAL ★ 4/10
$34.47 $35.53▲ +3.08%▲ +2.97%$35.71 (+3.60%)
Aug 28, 2026
4w ago
S-4
NEUTRAL ★ 6/10
$34.93 $34.32▼ −1.75%▼ −1.60%$35.71 (+2.23%)
Aug 3, 2026
8w ago
425 / 8-K
BULLISH ★ 8/10
$37.37 $38.47▲ +2.94%▲ +0.92%$35.71 (−4.44%)
Aug 3, 2026
8w ago
425
BULLISH ★ 8/10
$37.37 $38.47▲ +2.94%▲ +0.92%$35.71 (−4.44%)
Aug 3, 2026
8w ago
8-K
BULLISH ★ 8/10
$37.37 $38.47▲ +2.94%▲ +0.92%$35.71 (−4.44%)
Aug 3, 2026
8w ago
425 / 8-K
BULLISH ★ 7/10
$37.37 $38.47▲ +2.94%▲ +0.92%$35.71 (−4.44%)
Jul 23, 2026
10w ago
Press Release
NEUTRAL ★ 2/10
$40.51 $40.22▼ −0.72%▼ −1.19%$35.71 (−11.85%)
Jun 12, 2026
16w ago
Insider Cluster
NEUTRAL ★ 4/10
$38.40 $38.32▼ −0.21%▲ +1.17%$35.71 (−7.01%)
May 15, 2026
20w ago
8-K
NEUTRAL ★ 3/10
$36.54 $37.81▲ +3.48%▲ +1.86%$35.71 (−2.27%)
May 4, 2026
21w ago
8-K
NEUTRAL ★ 3/10
$38.98 $38.84▼ −0.36%▼ −3.30%$35.71 (−8.39%)
Showing 10 of 18

US Market Status

Market Closed — Opens Mon (64h 38m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access